February 9, 2018
Kyowa Hakko Kirin posted higher sales and profits in 2017 as it pulled in increased milestone payments from AstraZeneca for the asthma treatment benralizumab, with lower R&D costs following the termination of its tivantinib program also lending support. The company...read more